摘要
【目的】比较帕利哌酮缓释片与喹硫平治疗首发精神分裂症的临床疗效与安全性。【方法】106例首发精神分裂症患者随机分为两组，分别予以帕利哌酮缓释片与喹硫平治疗，疗程8周。采用阳性和阴性症状量表（PANSS）、副反应量表（TESS）评定疗效和不良反应。【结果】治疗8周，帕利哌酮组的有效率为81．1％，喹硫平组的有效率为79．2％，两组的差异无统计学意义。【结论】帕利哌酮缓释片与喹硫平治疗首发精神分裂症疗效相仿，能有效改善阳性症状及阴性症状，安全性高。
[Objective]To explore the clinical efficacy and safety of paliperidone extended-release tablet s in the treatment of first episode schizophrenia. [Methods]Totally 106 cases of first episode schizophrenia were randomly divided into two groups which received paliperidone extended-release tablet or quetiapine for 8 weeks, respectively. The clinical efficacy of patients was assessed with positive and negative syndrome scale （PANSS） and the side effects were evaluated with treatment emergent symptome scale（TESS）. [Results]Af- ter 8-week treatment, the effective rate of paliperidone extended-release tablet and quetiapine were 81.10% and 79.2 %, respectively. There was no significant difference between two groups. [Conelusion]Paliperidone extended-release tablet is as effective as quetiapine for the treatment of first episode schizophrenia, and can effectively improve positive and negative symptoms, and its safety is high.
出处
《医学临床研究》
CAS
2010年第12期2284-2286,共3页
Journal of Clinical Research
